A Clinical Trial of Thai Herbal Medicine as Post-exposure Prophylaxis for COVID-19: A pilot study

Suppachai Tiyaworanant and all other members of the research group0 个研究点开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1.Male or female aged 18 years and over.
•2.The individual must have been in close contact with a patient confirmed to have COVID-19 (referred to as the reference patient) for no more than 7 days
•3.While in close contact with a with a patient confirmed to have COVID-19 and did not wear a mask. (High risk) with one of the following characteristics
•3.1Provide close care to reference patients
•3.2Physical close contact with reference patients
•3.3Living with the reference patient
•3.4Sitting with a reference patient in an enclosed space, at a distance of no more than 2 meters, with or without direct contact for at least 1 hour.
•3.5Direct contact with body secretions of reference patients, such as mucus, saliva, tears, urine, and feces.
•4.Have complete awareness and be able to know, understand and make decisions.

•1.was diagnosed and required hospital treatment
•2.Tested with RT-PCR and confirmed to be infected with COVID-19.
•3.Have a history of allergic reaction to herbs that are ingredients in the recipe
•4.Have a history of allergic reaction to the proteins that make up the capsules
•5.Are pregnant or have had a positive pregnancy test result
•6.Having complete blood count, liver and kidney function that is abnormal from the standard values that the hospital considers or according to the doctor's opinion that such values are abnormal cannot be entered into the research process.
•7.Intend to use other herbal medicines for treatment such as Andrographis paniculata and Krachai.

发起方

Suppachai Tiyaworanant and all other members of the research group